ASCO oncology conference: Medivation (MDVN -0.6%) and partner Astellas (OTCPK:ALPMY) say their enzalutamide drug for advanced prostate cancer met secondary endpoints in a Phase 3 study. Medivation last month said it has applied for FDA approval to use enzalutamide in men with advanced prostate cancer who had undergone chemo. (see Zytiga)